Viropace Tablet

Introduction

Viropace is a prescription medication that contains the active ingredient Mesterolone. It is available under the brand name Viropace. This medication is primarily used to treat conditions related to insufficient production of male hormone testosterone.

Uses

Viropace is prescribed for a variety of conditions, including hypogonadism (a condition where the body does not produce enough testosterone), infertility due to low sperm count, and delayed puberty in boys. It may also be used to help enhance muscle growth and improve athletic performance in certain cases.

Dosage and Administration

The dosage of Viropace will vary depending on the specific condition being treated and individual patient factors. Follow the instructions provided by your healthcare provider. Typically, the recommended dose for adults is 25-50 milligrams per day, divided into two or three smaller doses. The duration of treatment will also be determined by your healthcare provider.

Viropace should be taken orally with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet unless directed by your healthcare provider.

Mechanism of Action

Mesterolone, the active ingredient in Viropace, belongs to a class of medications known as androgens. It works by binding to androgen receptors in the body, which helps stimulate the production of testosterone. This helps to restore hormonal balance and alleviate symptoms associated with testosterone deficiency.

Side Effects

Common side effects may include acne, oily skin, increased body or facial hair growth, and changes in sexual desire. These side effects are usually mild and temporary.

Serious side effects are rare but may include liver problems, mood changes, and allergic reactions. If you experience any of these serious side effects, seek medical attention immediately.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including over-the-counter drugs, herbal supplements, and vitamins. Viropace may interact with certain medications such as anticoagulants, insulin, and corticosteroids. These interactions can affect the way Viropace works or increase the risk of side effects. Your healthcare provider will carefully consider these interactions when prescribing Viropace.

Precautions

Before starting Viropace, inform your healthcare provider about any pre-existing medical conditions, allergies, or if you are pregnant or breastfeeding. This medication may not be suitable for everyone, especially those with liver problems, prostate cancer, or breast cancer.

Viropace should not be used by women, as it is specifically indicated for male hormone therapy. Avoid using this medication if you have a known allergy to Mesterolone or any other ingredients in the tablet.

Storage

Patient Tips

• Follow the dosage instructions provided by your healthcare provider and do not exceed the recommended dose.
• If you forget to take a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• It may take several weeks of regular use for the full benefits of Viropace to be observed. Continue taking the medication as prescribed, even if you start feeling better.
• If you experience any unusual or bothersome side effects, contact your healthcare provider for further guidance.
• Do not share your medication with others, as it is specifically prescribed for your individual condition.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Mesterolone (International database) (Drugs.com) [Accessed 2 Jun. 2024] (online) Available at:
• Baran L, Przegaliński E. Psychopharmacological profile of mesterolone. Pol J Pharmacol Pharm. 1981 Oct;33(3):299-303. [Accessed 10 Jun. 2024] Available at:
• Ho EN, Leung DK, Leung GN, Wan TS, Wong HN, Xu X, Yeung JH. Metabolic studies of mesterolone in horses. Anal Chim Acta. 2007 Jul 16;596(1):149-55. doi: 10.1016/j.aca.2007.05.052. Epub 2007 Jun 3. [Accessed 19 Jun. 2024] Available at:
• Lu J, Fernández-Álvarez M, Yang S, He G, Xu Y, Aguilera R. New potential biomarkers for mesterolone misuse in human urine by liquid chromatography quadrupole time-of-flight mass spectrometry. J Mass Spectrom. 2015 Jan;50(1):153-9. doi: 10.1002/jms.3508. [Accessed 11 Jun. 2024] Available at: